Research Center for High Performance Sport. Catholic University of Murcia
La Ñora, Murcia, 30830, Spain
NCT Number: NCT05295836
This clinical study evaluates the acute effect of glycerol ingestion on performance (power output), weight, urine specific gravity, biochemical (antioxidants and lactate) and metabolic (indirect calorimetry) markers in international athletes in hot conditions. The investigators hypothesized that acute glycerol ingestion can prevent performance loss (power generated at submaximal intensity) in hot conditions. To justify this hypothesis, the investigators will measure the aforementioned markers, which could establish a cause-effect relationship between acute glycerol intake and decreased performance loss in hot conditions.
Looking for future studies?
Notify Me25 year–35 year
Male
Interventional
Not applicable
La Ñora, Murcia, 30830, Spain
All participants will be informed about the procedures and provide signed informed consent. The study will be conducted according to the guidelines of the Helsinki Declaration for Human Research and the protocol was approved by the Ethics Committee/Institutional Review Catholic University of Murcia (Code: CE091802).
Study design
This is a randomized crossover study. There are 3 types of intervention: water intake of 26 mL/kg/weight at 16°C (CON), 26 mL/kg/weight + placebo at 28°C (PLA) and intake of 1.2 g glycerol + 26 mL/kg/weight at 28°C (GLY). In addition, athletes will be instructed to take a individualized diet in relation to macronutrients (verified by dietary record) and they will follow their adjusted training schedule so that there would be no effect on the tests. Participants in both groups will be instructed not to consume supplements 3 weeks prior to the start of the study.
Procedures
Participants will visit the laboratory on five occasions. Visit 1 consists of a medical examination and a blood draw to determine health status. At visit 2, after a dinner the night before and a standard breakfast, an incremental test will be performed to determine the exercise zones in the rectangular test. At visits 3, 4 and 5, a record of the diet (individually set) will be performed regarding the former 7 days, followed by a rectangular treadmill test.
Visit 1:
Health status blood test: A general blood test will be performed. The blood will be drawn through a vein. (Fasting) Medical examination: A medical history of family and personal history, an electrocardiogram (ECG) at rest and a medical examination (auscultation, blood pressure, etc.) will be carried out to certify that the person is healthy and is not at risk to participate in the study. (Fasting)
Visits 2:
Incremental test with final ramp test will be performed on a cycle ergometer using a metabolic cart (Metalyzer 3B. Leipzig, Germany) to determine maximal fat oxidation zone (FatMax), ventilatory thresholds 1 (VT1) and 2 (VT2) and maximal oxygen consumption (VO2max). Participants will begin cycling at 35W for 2 min, increasing then by 35W every 2 min until RER>1.05, initializing then the final ramp (+35W·min-1) until exhaustion.
Visits 3:
The rectangular test will be performed on a treadmill using the speed values obtained in the incremental test (15 sets x 2 min at 95% with 2:30 recovery at 85% of maximum speed between sets). Cardiorespiratory variables (VO2, VCO2, VO2R, VE/VO2, VE/VCO2, VE/VCO2, respiratory coefficient, respiratory frequency, carbohydrate oxidation (CHO), fat oxidation (FAT), running economy and energy expenditure) will be determined in the 1st, 5th, 10th and 15th series.
For power measurement, each participant will wear the Stryd power meter, which is an inertial sensor (9.1 g) mounted on the foot, firmly attached to the shoe and according to the manufacturer's recommendations. The device stores at a sampling rate of 1 Hz the following variables: estimated power (PO), pace, cadence, leg sprint stiffness (LSS), form power, form power ratio, ground contact time (GCT), vertical oscillation, stride length. These variables will then be determined in the 1st, 5th, 10th and 15th series of the rectangular test. According to information from the Stryd team, the device is operational out of the box and should not require any calibration, accepting a measurement error of 3 percent. Participants will fill in their height and body mass prior to use, which is required for PO estimation. The firmware version that will be used is 2.1.16 (released in August 2020).
For lactate and antioxidant measurements, a Lactate Pro 2 meter and eBQC lab will be used on finger capillary blood at rest, after the 5th, 10th and after completion of the rectangular test.
For body temperature, the investigators will use an infrared thermographic camera (FLIR) to measure heat distribution (head, trunk, lower and upper limbs in both anterior and posterior aspects of the body).
Urine Samples Urine will be collected from the intake of water or water + glycerol or water + placebo until the start of the rectangular test and up to one hour after the rectangular test. The volume of urine excreted pre and post rectangular test will be recorded and the urine specific gravity will be analyzed.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.
Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
Time frame: Throughout study completion, an average of 3 weeks
Record body weight before and after the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record urine specific gravity by means a digital refractometer (Atago) before and after the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record the power produced by means the stryd sensor (shoe) in the 1st, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record body temperature by thermography of the head, trunk, and lower limbs, anterior and posterior in rest, after 5th and 10th series, and after completion of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record lactate in rest, after 5th and 10th series, and after completion of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record the antioxidant markers in rest, after 5th and 10th series, and after completion of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record the heart rat in rest,1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record the oxygen uptake (L/min) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record the carbon dioxide exhalation (L/min) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record respiratory exchange ratio in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record ventilation (L/min) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record fat oxidation (g/h) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record carbohydrate oxidation (g/h) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record respiratory frequency (breaths/min) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record energy expenditure (kcal/h) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record ventilatory equivalents for oxygen (L/min) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record ventilatory equivalents for carbon dioxide (L/min) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record oxygen consumption relative to weight (mL/min/kg) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record cadence (steps per minute) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record leg spring stiffness (kN/m) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record form power ratio in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record form power (W) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record ground contact time (ms) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record vertical oscillation (cm) in 1th, 5th, 10th and 15th series of the rectangular test
Time frame: Throughout study completion, an average of 3 weeks
Record power output relative to weight (W/kg) in 1th, 5th, 10th and 15th series of the rectangular test
Francisco Javier Martínez Noguera
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04230824
Body Weight, Body Weight Changes
Chapel Hill, North Carolina, United States
View Trial DetailsNCT07412951
Performance Enhancing Product Use
Taichung, Taiwan
View Trial DetailsNCT07033611
Dialysis; Complications, Performance Enhancing Product Use
Puerto Aisén, Región de Aysen, Chile
View Trial DetailsNCT06688032
Bone Health, Performance Enhancing Product Use
Oslo, Norway
View Trial Details